The Fifth IFSO Global Registry Report (2019) has been released at the XXIV World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in Madrid, Spain. Published by Dendrite Clinical Systems, under the auspices of the IFSO, the publication reports data from more than 60 countries on over 833,000 operations including baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric surgery.
Dendrite Clinical Systems has announced the installation of its National Bariatric Surgical Registry software at the Sheik Al Jaber Al Sabah Hospital, in Kuwait. The Sheik Al Jaber Al Sabah Hospital, opened by His Highness the Amir Sheikh Sabah Al-Ahmad Al- Jaber Al-Sabah in November 2018, consists of five towering 10-stories structures built on a 220,000 square meters and has a hospital bed capacity of around 1,160 with 36 operation rooms, a medical centre, a helipad and a parking lot accommodating some 5,000 vehicles.
Dendrite Clinical Systems and the Queen Mary Hospital in Hong Kong have launched the Asian Hypospadias Outcome Registry (AHOR), is a prospective web-based patient registry that will collect, record and analyse the treatment and outcomes of patients undergoing surgical repair.
Dendrite Clinical Systems has launched its ‘One-button push’ outcomes module, allowing clinicians to instantly produce their outcomes with the push of a single button. This enhancement is the latest in a series of advances incorporated into the company’s clinical registry software.
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 40 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite Clinical Systems – in collaboration with Haemotology Cancer Care (UCLH Charity), the Royal Free Charity, HaemSTAR (an organisation researching non-malignant haematology) and MPN Voice – have launched the MASCOT (Myeloproliferative Neoplasm Splanchnic Vein Thrombosis, MPN-SVT) Registry, a UK wide registry for patients with myeloproliferative diseases suffering from splanchnic or abdominal vein thrombosis.
Sapphire Medical Clinics and Dendrite Clinical Systems launch UK Medical Cannabis Registry
Sapphire Medical Clinics and Dendrite Clinical Systems have launched the UK Medical Cannabis Registry, an initiative that is designed to rapidly expand the evidence base for medical cannabis in the UK and decrease the cost of access for patients. The launch will collect and analyse clinical information on patients taking medical cannabis treatments for all recognised eligible conditions.
“We delighted to be part of this exciting registry that will provide much needed evidence about the efficacy of medicinal cannabis,” said Dr Peter Walton, Managing Director of Dendrite Clinical Systems. “This registry will collect and record data on cannabis-based medicinal products and help determine the how effective medicinal cannabis use is for a variety of life-changing and debilitating conditions.”
This online registry was developed by Dendrite using their ‘Intellect Web’ software, allowing users to enter patient data online, using a range of modern html-5 compatible web browsers, without the need to install additional software or perform any complex system configurations. The registry can be programmed to generate lists for pending follow-ups, letters and prompts to patients and reminder emails to physicians.
Dendrite has also developed and incorporated a novel, interactive, data collection system giving patients the freedom to report their PROMS and AE/SE electronically using their smartphone, negating the needs for costly and time-consuming visits to healthcare specialists. The registry will also collect data on patient demographics, co-morbidities, current medications, smoking/alcohol consumption, occupation, symptoms requiring cannabis, the cannabis product used (dose, brand etc).
“We are very proud to launch our Real World Evidence Platform which ultimately aims to provide the data to allow patients to access cannabis-based medicines on the NHS for all the conditions in which there is proven clinical benefit,” said Dr Mikael Sodergren, Managing Director and Academic Lead at Sapphire Clinics. “Whilst we are actively involved in setting up randomised controlled trials, our Real World Evidence Platform will provide faster access to high quality data and will provide an unparalleled resource for clinicians, regulators and commercial stakeholders.”
The Registry forms part of the Sapphire Real World Evidence Platform incorporating patient-generated health data, which also includes novel sensing and digital biomarkers. In recognition of their contribution to building the most comprehensive such dataset globally, the first thousand patients’ as part of the Sapphire Access Scheme are eligible for a significant reduction in the appointment cost. The UK Medical Cannabis Registry will also be free to contribute to for any patient in the UK with a prescription who wants to advance the science of medical cannabis. Patients on the scheme will also receive greater insight into how their treatment is affecting them via the Real World Evidence Platform.
“There are an estimated 1.4 million medical cannabis patients in the UK and with this initiative we hope to make it more affordable for them to access medication through a recognised clinic where we can carefully monitor their treatment,” said Dr Michael Platt, Medical Director of Sapphire Clinics. “Alongside significant patient demand, there is a need to provide clinicians with a prescribing formulary based on the best data available whilst we wait for clinical trials.”
For further enquiries about the UK Medical Cannabis Registry and how to enrol a patient, please contact: registry@sapphireclinics.com
